Themis Medicare commences supply of Diclofenac Sodium injection to Novartis

Themis Medicare Ltd. | Pharmaceuticals & Drugs | Healthcare | BSE: 530199 | NSE: THEMISMED

05 Nov 2014 Evaluate

Themis Medicare has commenced the supply of Diclofenac Sodium 75 mg per ml Injection as finished dosage pharmaceutical form to Novartis India with effect from October, 2014. The company had earlier on August 16, 2013 executed a Supply & Distribution Agreement with Novartis India for the same.

Themis Medicare is also engaged in supplying its research formulations to well known Pharmaceutical companies in India namely Alkem Lab, Fulford, Intas Pharmaceuticals, IPCA Lab, Cadila Healthcare, Aristo Pharma, Mankind Pharma, Shreya Lifesciences, Nicholas Piramal, Unichem Lab, etc.

Peers

Company Name	CMP
Sun Pharma. Inds.	1853.50
Dr. Reddys Labs.	1202.80
Cipla	1397.20
Lupin	2090.00
Zydus Lifesciences	1202.00
View more..

Name of the IA registered with SEBI:	The Alchemists Ark Pvt. Ltd.
Logo:
Trade/Brand Name of IA:	MoneyWorks4Me Investment Advisers
Brand Logo:
SEBI Registration Number:	INA000013323 Validity – May 16, 2019 – Perpetual
Registration:	Non-Individual
BSE Enlistment No:	1187
Address:	B-101, Signet Corner Building, Balewadi Phata, Baner, Pune, Maharashtra 411045

Compliance Officer Details:	Name: Shrikant Jagtap Email: shrikant.jagtap@moneyworks4me.com	Telephone: +919860359463 Address: Same as IA
Grievance Officer Details:	Name: Mukta Vaze Email: mukta.vaze@moneyworks4me.com	Telephone: +919860919463 Address: Same as IA
Principal Officer Details:	Name: Atharva Bhide Email: atharva.bhide@moneyworks4me.com	Telephone: +919175899463 Address: Same as IA
Standard Warning:	Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Disclaimer:	Registration granted by SEBI, enlistment with exchange and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.